Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

BACKGROUND: The integrase inhibitor dolutegravir could have a major role in future antiretroviral therapy (ART) regimens in sub-Saharan Africa because of its high potency and barrier to resistance, good tolerability, and low cost, but there is uncertainty over appropriate policies for use relating t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet HIV
Asıl Yazarlar: Phillips, Andrew N, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel, Wensing, Annemarie, Lundgren, Jens D, De Luca, Andrea, Pillay, Deenan, Mellors, John, Cambiano, Valentina, Bansi-Matharu, Loveleen, Nakagawa, Fumiyo, Kalua, Thokozani, Jahn, Andreas, Apollo, Tsitsi, Mugurungi, Owen, Clayden, Polly, Gupta, Ravindra K, Barnabas, Ruanne, Revill, Paul, Cohn, Jennifer, Bertagnolio, Silvia, Calmy, Alexandra
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier B.V 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6361866/
https://ncbi.nlm.nih.gov/pubmed/30503325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(18)30317-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller